NASDAQ:CDTX - Nasdaq - US1717572069 - Common Stock - Currency: USD
Overall CDTX gets a fundamental rating of 3 out of 10. We evaluated CDTX against 551 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CDTX as it has an excellent financial health rating, but there are worries on the profitability. CDTX is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -95.44% | ||
ROE | -129.15% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 9.32 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.87 | ||
Quick Ratio | 3.87 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
61.99
+0.22 (+0.36%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 4138.14 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 8.82 | ||
P/tB | 8.82 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -95.44% | ||
ROE | -129.15% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 46.9% | ||
Cap/Sales | 35.1% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.87 | ||
Quick Ratio | 3.87 | ||
Altman-Z | 9.32 |